<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932460</url>
  </required_header>
  <id_info>
    <org_study_id>2021332GD</org_study_id>
    <nct_id>NCT04932460</nct_id>
  </id_info>
  <brief_title>Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy</brief_title>
  <acronym>Asclepius</acronym>
  <official_title>A Prospective Multi-center Study: Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy After Neoadjuvant Therapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Seventh Affiliated Hospital of Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Guangdong Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      False negative rate (FNR) in patients who has accepted neoadjuvant therapy is high. Blue dye&#xD;
      and radioisotope as dual-tracer can decrease FNR. Several large clinical trials showed that&#xD;
      using dual trace with blue dye and radioisotope can reduce the FNR to less than 10%. But&#xD;
      radioisotope is still not approved in China and can cause radiocontamination. A novel&#xD;
      dual-tracer which can decrease the FNR in patients after neoadjuvant therapy is urged to be&#xD;
      explored. Contrast enhanced ultrasonography (CEUS) can make the lymphatic drainage path and&#xD;
      sentinel lymph nodes visible. Retrospective studies found that CEUS can locate SLN precisely.&#xD;
      So this clinical trial aim to evaluate FNR, detective rate and numbers of SLN by using CEUS&#xD;
      combined with blue dye as dual-tracer in sentinel lymph node biopsy in breast cancer patients&#xD;
      after neoadjuvant therapy and the accuracy of CEUS for the diagnosis of lymph node metastasis&#xD;
      before and after neoadjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate</measure>
    <time_frame>6 months</time_frame>
    <description>The false negative rate (FNR) of sentinel lymph node biopsy using dual-tracer with CEUS and blue dye after neoadjuvant chemotherapy in invasive breast cancer patients.&#xD;
The FNR is calculated as the number of false negative cases divided by the number of false negative plus true positive cases and then multiplied by 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The detective rate of sentinel lymph node biopsy</measure>
    <time_frame>6 months</time_frame>
    <description>The detective rate of SLNB after neoadjuvant therapy when using blue dye and CEUS lymphatic mapping as dual tracer.&#xD;
The detective rate is calculated as the number of patients in whom SLN can be detected during SLNB divided by the number of patients with the treatment of SLNB and then multiplied by 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average numbers of sentinel lymph node</measure>
    <time_frame>6 months</time_frame>
    <description>The average numbers of sentinel lymph node is calculated as the number of all SLNs detected during SLNB divided by the number of patients received SLNB and then multiplied by 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The accuracy of CEUS in evaluation of axillary lymph nodes in breast cancer</measure>
    <time_frame>6 months</time_frame>
    <description>The accuracy of CEUS in evaluation of axillary lymph nodes in breast cancer patients before and after neoadjuvant therapy.&#xD;
The accuracy rate is calculated as the number of true positive plus true negative cases divided by the number of patients then multiplied by 100%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Sentinel Lymph Node Biopsy</condition>
  <arm_group>
    <arm_group_label>CEUS+blue dye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The included patients will accept essential tests and CEUS before and after neoadjuvant chemotherapy to evaluate axillary lymph nodes status. When patients finish neoadjuvant therapy, SLNB with or without axillary lymph node dissection will be performed using CEUS lymphatic mapping to mark SLN on the skin combined with blue dye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CEUS</intervention_name>
    <description>CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.</description>
    <arm_group_label>CEUS+blue dye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blue dye</intervention_name>
    <description>Before operation, blue dye is injected for sentinel lymph node mapping.</description>
    <arm_group_label>CEUS+blue dye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old female；&#xD;
&#xD;
          -  ECOG：0 - 1；&#xD;
&#xD;
          -  Biopsy confirmed invasive breast cancer；&#xD;
&#xD;
          -  cT1-4N0-3；&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer；&#xD;
&#xD;
          -  Received ipsilateral axillary surgery previously；&#xD;
&#xD;
          -  During pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Lin</last_name>
    <phone>13076873871</phone>
    <email>linying3@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Shan</last_name>
    <phone>18565396593</phone>
    <email>szsysu@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Sun Yat-Sen university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.</citation>
    <PMID>23683750</PMID>
  </results_reference>
  <results_reference>
    <citation>Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1.</citation>
    <PMID>25452445</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ying Lin</investigator_full_name>
    <investigator_title>Vice Director of Department of Breast Surgery</investigator_title>
  </responsible_party>
  <keyword>contrast enhanced ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

